The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Open accessAbstract
Purpose: This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years of follow-up and to explore the risk of second primary malignancies. Patients and Methods: In all, 682 patients received up to nine 6-week cycles of VMP or MP and were then observed every 12 weeks or less. Data on second primary malignancies were collected by individual patient inquiries at all sites from 655 patients. Results: After median follow-up of 60.1 months (range, 0 to 74 months), there was a 31% reduced risk of death with VMP versus MP (hazard ratio [HR], 0.695; P < .001; median OS 56.4 v 43.1 months). OS benefit with VMP was seen across prespecified patient subgroups (age ≥ 75 years, stage III myeloma, creatinine clearance < 60 mL/min). Sixty-three percent of VMP patients and 73% of MP patients had received subsequent therapy. Time to next therapy (median, 30.7 v 20.5 months; HR, 0.557; P < .001) was longer with VMP than with MP. Among patients who received subsequent therapies, survival from start of subsequent therapy was similar following VMP (median, 28.1 months) or MP (median, 26.8 months; HR, 0.914). Following VMP/MP, incidence proportions of hematologic malignancies (1%/1%) and solid tumors (5%/3%) and exposure-adjusted incidence rates (0.017/0.013 per patient-year) were similar and were consistent with background rates. Conclusion: VMP resulted in a significant reduction in risk of death versus MP that was maintained after 5 years' follow-up and despite substantial use of novel-agent-based salvage therapies. There is no emerging safety signal for second primary malignancies following VMP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Self-citationFacon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citationCavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Self-citationContinuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
Self-citationRecent major improvement in long-term survival of younger patients with multiple myeloma
Brenner, H., Gondos, A., & Pulte, D. (2008) · Blood · doi:10.1182/blood-2007-08-104984 · Cited by 535
Harousseau, J.-L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 532
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Self-citationAvet-Loiseau, H., Leleu, X., Roussel, M., Moreau, P., Guerin-Charbonnel, C., Caillot, D., Marit, G., Benboubker, L., Voillat, L., Mathiot, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3945 · Cited by 424
Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 381
The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia
Bergsagel, D. E., Bailey, A. J., Langley, G. R., MacDonald, R. N., White, D. F., & Miller, A. B. (1979) · New England Journal of Medicine · doi:10.1056/nejm197910043011402 · Cited by 376
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 358
Self-citationFayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J.-Y., Gimsing, P., Termorshuizen, F., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341669 · Cited by 272
Self-citationWijermans, P., Schaafsma, M., Termorshuizen, F., Ammerlaan, R., Wittebol, S., Sinnige, H., Zweegman, S., van Marwijk Kooy, M., van der Griend, R., Lokhorst, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1610 · Cited by 260
Pedersen-Bjergaard, J., Andersen, M. K., & Christiansen, D. H. (2000) · Blood · doi:10.1182/blood.v95.11.3273 · Cited by 245
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I. M., Forsberg, K., Gulbrandsen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237974 · Cited by 230
Clinically relevant end points and new drug approvals for myeloma
Anderson, K. C., Kyle, R. A., Rajkumar, S. V., Stewart, A. K., Weber, D., Richardson, P., & Myeloma, O. B. O. T. A. /. P. O. C. E. I. M. (2008) · Leukemia · doi:10.1038/sj.leu.2405016 · Cited by 225
Self-citationDong, C., & Hemminki, K. (2001) · British Journal of Cancer · doi:10.1038/sj.bjc.6691998 · Cited by 202
Mailankody, S., Pfeiffer, R. M., Kristinsson, S. Y., Korde, N., Bjorkholm, M., Goldin, L. R., Turesson, I., & Landgren, O. (2011) · Blood · doi:10.1182/blood-2011-05-355743 · Cited by 200
Kastritis, E., Zervas, K., Symeonidis, A., Terpos, E., Delimbassi, S., Anagnostopoulos, N., Michali, E., Zomas, A., Katodritou, E., Gika, D., et al. (2009) · Leukemia · doi:10.1038/leu.2008.402 · Cited by 187
Self-citationBarlogie, B., Attal, M., Crowley, J. J., van Rhee, F., Szymonifka, J. D., Moreau, P., Durie, B. G. M., & Harousseau, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6081 · Cited by 153
Dimopoulos, M. A., Richardson, P. G. G., Brandenburg, N. A., Yu, Z., Weber, D. M., Niesvizky, R., & Morgan, G. J. (2012) · Blood · doi:10.1182/blood-2011-08-373514 · Cited by 149
Self-citationCuzick, J. M., Erskine, S., Edelman, D., & Galton, D. A. G. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.107 · Cited by 143
Beksaç, M., Haznedar, R., Firatli‐Tuglular, T., Özdoğu, H., Aydoğdu, İ., Konuk, N., Sucak, G. T., Kaygusuz, I., Karakuş, S., Kaya, E., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01524.x · Cited by 143
Treatment Options for Relapsed and Refractory Multiple Myeloma
Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 130
Self-citationExpected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Brenner, H., Gondos, Á., & Pulte, D. D. (2009) · Haematologica · doi:10.3324/haematol.13782 · Cited by 120
Mateos, M., Hernández‐Rivas, J. M., Hernández, M., Gutierrez, N. C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12106 · Cited by 86
Self-citationHasskarl, J., Ihorst, G., Pasquale, D. D., Schröttner, P., Zerweck, A., Wäsch, R., & Engelhardt, M. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.529207 · Cited by 71
Mateos, M., Gutierrez, N. C., Martín-Ramos, M.-L., Paiva, B., Montalbán, M.-Á., Oriol, A., Martínez‐López, J., Teruel, A. I., Bengoechea, E., Martín, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-345801 · Cited by 58
Self-citationEinsele, H., Liebisch, P., Langer, C., Kropff, M. H., Wandt, H., Jung, W. E., Kröger, N. M., Engelhardt, M. M., Ostermann, H., Mügge, L., et al. (2009) · Blood · doi:10.1182/blood.v114.22.131.131 · Cited by 43
Self-citationVenner, C. P., Connors, J. M., Sutherland, H. J., Shepherd, J. D., Hamata, L., Mourad, Y. A., Barnett, M. J., Broady, R. C., Forrest, D. L., Hogge, D. E., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.531409 · Cited by 35
Siciliano, A., Malpeli, G., Platt, O., Lebœuf, C., Janin, A., Scarpa, A., Olivieri, O., Amato, E., Corrocher, R., Beuzard, Y., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.028506 · Cited by 31
Richardson, P. G. G., Laubach, J. P., Mitsiades, C. S., Schlossman, R. L., Hideshima, T., Redman, K., Chauhan, D., Ghobrial, I. M., Munshi, N. C., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08791.x · Cited by 24
Self-citationOptimising patient outcomes in myeloma
Harousseau, J. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70010-4 · Cited by 4
Cited by
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationSchnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationPalumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615187 · Cited by 775
Self-citation
Metadata
- Authors
- San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., Dmoszynska, A., Abdulkadyrov, K. M., Delforge, M., Jiang, B., Mateos, M.-V., Anderson, K. C., Esseltine, D.-L., Liu, K., Deraedt, W., Cakana, A., van de Velde, H., & Richardson, P. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-02-01
- Volume
- 31
- Issue
- 4
- Pages
- 448-455
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158106888
- Cited by
- 265
- References
- 40
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.